Cell Cycle/Checkpoint

A microtubule destabilizer

An internal standard for the quantification of betaxolol

A sulfated phenolic acid

J27644 is an inhibitor of histone deacetylase 6 (HDAC6; IC50 = 10 nM).

UK 122 is an inhibitor of urokinase-type plasminogen activator (uPA; IC50 = 0.2 µM).

CYY292 is an inhibitor of PDGFRα, PDGFRβ, FGFR1, -2, and -3, (IC50s = 5.35, 4.6, 28, 28, and 78 nM, respectively).

DTPD-Q is an oxidized derivative of the antioxidant and methylphenyl substituted p-phenylenediamine DTPD.

PDIC-NN is an intermediate in the synthesis of PDIC-NS , an activator of stimulator of interferon genes (STING) with anticancer activity.

DPP-9 inhibitor 42 is an inhibitor of dipeptidyl peptidase 9 (DDP-9; IC50 = 0.0034 µM).

PDIC-NS is an activator of stimulator of interferon genes (STING).

Polysarcosine20 is an amine-functionalized hydrophilic polymer.

BI SF3 is a synthetic intermediate.

Carmustine-d8 is intended for use as an internal standard for the quantification of carmustine by GC- or LC-MS.

Rhein-13C6 is intended for use as an internal standard for the quantification of rhein by GC- or LC-MS.

TrkB agonist prodrug R13 (R13) is a prodrug form of the tropomyosin-related kinase B (TrkB) activator 7,8-dihydroxyflavone.

Debio 0123 is an inhibitor of the checkpoint kinase WEE1 (IC50 = 0.8 nM).

JQKD82 is a prodrug form of KDM5-C49, an inhibitor of Jumonji AT-rich interactive domain 1A (JARID1A), also known as lysine-specific demethylase 5A (KDM5A).

Alkyne-cyclo(RGDyK) is a clickable form of the αVβ3 integrin cyclic peptide ligand cyclo(RGDyK) .

PtdIns-(4,5)-P2 (1,2-dipalmitoyl)-d62 (sodium salt) is intended for use as an internal standard for the quantification of PtdIns-(4,5)-P2 (1,2-dipalmitoyl) (sodium salt) by GC- or LC-mass spectrometry.

FNIII14 is an inhibitor of cell adhesion and a peptide derived from the 14th type III repeat, which is part of heparin-binding domain 2, of human, mouse, and rat fibronectin.

Vinorelbine is an anti-mitotic drug, a semi-synthetic derivative of paclitaxel, that exerts its antitumor effect by inhibiting microtubule polymerization in tumor cells. Vinorelbine is primarily used to treat malignant tumors such as non-small cell lung cancer and metastatic breast cancer.